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CASE REPORT
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of VIP Levels after Hepatic Artery
Chemoembolization in a Patient with
Sandostatin Resistant VIPoma
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aHospital of Saint Raphael and bYale University School of Medicine, New Haven,
Connecticut
Vasoactive intestinal polypeptide secreting islet cell tumors (†VIPomas) are neuroendocrine
tumors that secrete excessive amounts of vasoactive intestinal polypeptide (VIP) that cause
distinct syndromes characterized by large-volume diarrhea, hypokalemia, and dehydration.
The annual incidence of these tumors is estimated to be about one per 10,000,000 individ-
uals in the general population. We report a successful treatment of VIPoma with hepatic
chemoembolization of a metastatic hepatic lesion evidenced by a reduction of VIP levels and
resolutions of symptoms in a patient with pancreatic VIPoma unresponsive to increased
doses of an octreotide analog.
INTRODUCTION
We would like to report a case in
which hepatic chemoembolization of a
metastatic hepatic lesion of VIPoma (Va-
soactive Intestinal Polypeptide secreting
islet cell tumor) leads to a reduction ofVIP
(Vasoactive Intestinal Polypeptide) levels
and resolution of symptoms in a patient
with pancreatic VIPoma unresponsive to
increased doses of an octreotide analog.
CASE REPORT
An 80-year-old Caucasian woman with
a history of VIPoma diagnosed in 1997 was
treated for a 3.5 cm lesion in the head of the
pancreasbyWhippleproceduresurgery(Fig-
ure1).Shetoleratedthesurgerywell,except
for the development of diabetes controlled
with insulin postoperatively. In December
2004, follow-up CT imaging showed a new
2.5 cm mass in the bed of the pancreas. She
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Keywords: Hepatic artery chemoembolization, VIPomaunderwent another resection with positive
margins and one out of three lymph nodes
positive for malignancy, for which levels of
VIPwere>400pg/ml(normal<75),chromo-
granin A 16.2 U/L (<31), gastrin16 pg/ml
(<110)andserotonin15ng/ml(<71).Follow-
up serial octreotide scans showed stable dis-
ease. In May 2005, a follow-up octreotide
scan showed the same unresectable retropan-
creatic tumor with new involvement of the
right hepatic lobe (Figure 2). Due to the long
andindolentcourseofthediseaseandbecause
thepatientwasasymptomatic,shewastreated
with Sandostatin long acting (LAR) depot
monthly.InSeptember2006,thepatientcom-
plainedofworseningdiarrhea,upto10bowel
movements in 24 hours. Laboratory data
showedthatVIPlevelswerestill>400pg/ml.
Patient was re-started on a loading dose of
short-acting Sandostatin at 150 micrograms
subcutaneously every eight hours for two
weeks, followed by LAR Sandostatin 20 mg
intramuscularlyevery28days.Duetopersist-
entdiarrhea,thedoseofLARSandostatinwas
escalated by increments of 10 mg every 28
days to a maximum dose of 100 mg.TheVIP
levelscontinuedtobehigh(>400pg/ml),and
diarrhea transiently improved.Another flare-
upoccurredinMarch2008,manifestedbyin-
tractable diarrhea and severe metabolic
acidosis. Because there are no guidelines in
thetreatmentandfollow-upofthisdisease,we
elected to initiate treatment with 5 Fluo-
rouracil(5-FU)andstreptozocin,basedonre-
ports and success rates. No improvement of
diarrhea (consistency and frequency) was
notedonthistreatment.5-FUwaschangedto
capecetabine with the same results as 5-FU.
She underwent chemo-ablation with mito-
mycin c, cisplatin, and doxorubicin. Her hos-
pital course after the chemoablation was
complicated by pulmonary embolism, atrial
fibrillation, pneumonia, and vancomycin-re-
sistant enterococcus bacteremia. After treat-
ment, her diarrhea improved to less than two
stools per day. In addition, the VIPlevels de-
creasedto122pg/ml(Figure3).Threemonths
later, patient was started on temozolomide as
maintenance therapy.
DISCUSSION
VIPomas are neuroendocrine tumors
that secrete excessive amounts of VIP that
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Figure 1. Pathology specimen showing pancreatic islet cell tumor.cause distinct syndromes characterized by
large-volume diarrhea, hypokalemia, and
dehydration. The annual incidence of these
tumors is estimated to be about 1 per
10,000,000 individuals in the general popu-
lation [1].The mean age ofVIPoma patients
is 49 years. This syndrome is also called
Verner-Morrison syndrome, pancreatic
cholera, or WDHA (watery diarrhea, hy-
pokalemia, and achlorhydria) syndrome. In
addition to the WDHA, patients can present
with flushing secondary to the vasodilatory
effect of the VIP. These tumors are usually
solitary, more than 3 cm in diameter and
occur in the pancreas in 80 percent to 90 per-
cent of cases, mainly in the pancreatic tail
(50 percent to 75 percent) with
37 percent to 68 percent hepatic
metastasis at diagnosis. Demon-
stration of elevated levels (>75
pg/ml) of VIPconfirms diagno-
sis in the clinical setting [2,3].
For localizing and staging of
these tumors, somatostatin re-
ceptor scintigraphy with oc-
treotide scan has been
recommended as the best imag-
ing technique [4]. Treatment
preferences depend on the pres-
ence of metastasis. In metastatic
tumors, long-acting somato-
statin analogs are the drugs of
choice. Somatostatin analogs
are typically initiated at 20 mg
daily dosage, and gradual esca-
lation of the dose as needed, for
optimal control of symptoms, is
recommended [5]. Hepatic re-
section is indicated for the treat-
ment of metastatic liver disease
in the absence of diffuse bilobar
involvement, compromised
liver function, or extensive ex-
trahepatic metastases [6].
Other treatment options
have been described with no set
recommendations. Interferon-
alfa added to octreotide is used
as one of the modalities for
treatment of refractory diarrhea
in these patients [7]. Experi-
ences with chemotherapeutic agents are lim-
ited. Fjallskoga et al. concluded that
combined streptozotocin and liposomal dox-
orubicin is a safe and efficient treatment for
endocrine pancreatic tumors. The efficacy
seems to be comparable to that of combined
streptozotocin and doxorubicin; whereas,
the cardiac toxicity clearly favors using the
liposomal drug combination [8]. Streptozo-
tocin plus 5-fluorouracil produced objective
responses in 17 out of 31 (54 percent) pa-
tients with a median duration of response of
23 months [9].
Medical management with octreotide
analogs has proven useful in the manage-
ment of pancreatic islet cell tumors with un-
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Figure 2. Octreoscan from 5/17/05 shows uptake in the
right liver superior to the right kidney.resectable disease and/or metastases [10,11].
Neuroendocrine gastrointestinal tumors ex-
press somatostatin receptors (sstrs) in 80
percent to 90 percent of cases, and somato-
statin analogs have become increasingly im-
portant in the management of these patients.
Most of the currently available somatostatin
analogs bind to the sstr2 and sstr5 receptor
types and in higher doses to sst3 of the ssts
1-5 described. Clinical improvement during
somatostatin analog therapy is mainly me-
diated via a direct inhibitory effect on hor-
mone production from the tumors, seen in
30 percent to 70 percent of patients. Indirect
non-tumor mediated effects on peripheral
target organs contribute to the subjective im-
provement achieved in 30 percent to 70 per-
cent of patients. Significant improvement of
quality of life has been demonstrated with
long-acting depot formulations. There is lit-
tle or no effect on tumor growth during oc-
treotide therapy. Tumor shrinkage has been
reported in 10 percent to 20 percent of pa-
tients, but stabilization of tumor growth can
be achieved in about half of the patients in
eight to 16 months after starting treatment.
Induction of apoptosis has been reported by
octreotide analogs as a possible mechanism
of action on these tumors [12]. Octreotide
inhibits hormone secretion by various neu-
roendocrine tumors and may occasionally
reduce metastatic tumor burden [13]. Vary-
ing data exist about the quantitative reduc-
tion of tumor size and symptomatic relief.
Oberg et al. reported a significant tumor re-
sponse in <5 percent of patients but a symp-
tomatic response in 60 percent of patients
[14]. Maton et al. observed 83 percent symp-
tomatic response but fewer than 20 percent
reduction in tumor size [15]. A case report
by Kraenzlin et al. showed that long-acting
Sandostatin not only controlled the diarrhea
without side effects, but also appeared to
have possibly induced a reduction in
metastatic tumor size. Conventional meas-
ures of surgery, chemotheraphy, and hepatic
artery embolization ultimately failed to con-
trol the severity of diarrhea, resulting from
vasoactive intestinal polypeptide hyper-
secretion [16]. Cho and Vinik evaluated
tumor blood flow using angiography in eight
patients with different types of neuroen-
docrine tumors receiving octreotide. They
found a marked decrease in blood flow in
two patients with gastrinomas and two pa-
tients with VIPomas, with a hypothesis that
octreotide either decreases blood flow to
these tumors or decreases tumor size or hor-
monal secretion [17].
Contrary to all these reports,VIPhyper-
secretion kept elevating in our patient, al-
though long-acting octreotide analog doses
were increased. Similar to our report, Lam-
berts et al. reported two patients with
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Figure 3. Levels were consistently >400 pg/mL, and the patient was symptomatic on es-
calated dosing of Sandostatin. On introduction of TACE (Transcatheter Chemoemboliza-
tion) with mitomycin c, cisplatin and doxorubicin, patient became asymptomatic and VIP
levels decreased as shown in the graph.metastaticVIPomas developed resistance to
somatostatin analog with regard to clinical
and inhibitory effect [18]. An “escape phe-
nomenon” to somatostatin analog was no-
ticed for a few days with a usual response
after discontinuation of the treatment [19].
In another report, 10 patients with metastatic
pancreatic endocrine tumors were treated
with the long-acting somatostatin analog oc-
treotide.Three patients showed no response,
clinically or biochemically, and treatment
was, therefore, withdrawn. The seven re-
maining patients continued treatment for a
median period of 28 months (range 13-54
months). Treatment was initially effective,
symptoms improved, and the concentrations
of tumor-related hormones were reduced.
Worsening of symptoms and rising levels of
tumor-related hormone concentrations oc-
curred at a median of five months (range 1-
6 months) after the start of therapy and were
initially reversed by increasing the dose of
octreotide over a median of 10 months
(range 6-16 months). However, after a me-
dian of 13 months (range 5-34 months) at
the maximum dosage, symptoms recurred
and were no longer responsive to a further
increase in dosage of octreotide or other
therapeutic measures. All patients died
within five months once this “resistance
phase” of their illness had been reached
[20]. However, resistance was never con-
firmed on histological or biochemical stud-
ies. Arterial chemoembolization is
recommended for patients with significant
symptoms who have failed to respond to
more conservative therapy and are not surgi-
cal candidates [21].
For patients with hepatic metastasis,
initial expectant observation and medical
management of symptoms is appropriate in
view of the long and indolent course of the
disease.As mentioned earlier, hepatic resec-
tion is indicated for the treatment of metasta-
tic liver disease in the absence of diffuse
bilobar involvement, compromised liver
function, or extensive extrahepatic metas-
tases. VIPomas are often large or metasta-
sizing, but generally require surgical
debulking to alleviate hormonal symptoms
and have favorable survival outcomes [6].
In a clinical trial conducted by Eriksson et
al., patients having midgut, foregut carci-
noids and neuroendocrine pancreatic tu-
mors, treatment of liver metastases by
surgical resection and/or radiofrequency ab-
lation (RFA) was successful in patients with
midgut carcinoids with only less success in
reducing symptoms in patients with foregut
carcinoids or neuroendocrine tumors. In ad-
dition, patients with non-functioning neu-
roendocrine tumors may benefit from
debulking procedure to reduce morbidity
and improve survival. Proposal of surgical
debulking or RFAas means that limit proce-
dure-related morbidity and efficiently alle-
viate symptoms has been beneficial in these
patients, especially as this disease has a high
incidence of recurrence [6,22]. Azimuddin
et al. reported that hepatic arterial emboliza-
tion is the preferred management in these
cases [23]. Case et al. confirmed the finding
that hepatic artery embolization can be very
effective and durable as a treatment modal-
ity for patients with metastatic VIPomas (or
other neuroendocrine tumors) who are clin-
ically symptomatic from the effects of hor-
mone hypersecretion. It is applied as a
palliative technique in symptomatic patients
with unresectable hepatic metastasis [24].
Furthermore, the study of Gupta et al. at MD
Anderson has compared embolization alone
to chemoembolization of the hepatic artery
and has concluded that in pancreatic islet
cell tumors (without specifying the subtype
of the tumor), chemoembolization has im-
proved response rate by 50 percent com-
pared to 25 percent with embolization alone.
Moreover, chemoembolization of these tu-
mors had a survival benefit as compared to
embolization alone (31.5 months vs. 18.2
months) [25]. Yao et al. demonstrated that
for unresectable but liver dominant disease,
chemoembolization was the treatment of
choice, with median survival of 32 months
post chemoembolization and a five-year sur-
vival rate of 40 percent. Chemoembolization
effectively controlled tumor growth and al-
leviated symptoms in 90 percent of patients
[26].This modality helped in controlling the
symptoms of our patient. Moreover; theVIP
levels trended down as shown by the graph
31 Shaib: Reduction of VIP levels after hepatic artery chemoembolization in VIPomain Figure 3. Huang et al. concluded that
treatment for metastatic pancreatic islet cell
tumors require a multidisciplinary approach.
Metastasis of the tumor is not a contraindi-
cation for aggressive therapy. Combined cy-
toreductive surgery and TACE can relieve
symptoms and are of benefit for patients
with pancreatic islet cell tumors with liver
metastases [27].
Temozolomide is another treatment op-
tion for metastatic disease. As a monother-
apy, it has acceptable toxicity and
antitumoral effects in a small series of pa-
tients with advanced malignant neuroen-
docrine tumors with some radiologic
responses [28].
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